Breast cancer symposium set for San Antonio

November 19, 2000

More than 3,000 physicians and researchers from throughout the world are expected to participate in the 23rd Annual San Antonio Breast Cancer Symposium, December 6-9, in San Antonio. The Symposium is co-sponsored by the Cancer Therapy & Research Center (CTRC) and The University of Texas Health Science Center at San Antonio (UTHSCSA) whose affiliation forms the San Antonio Cancer Institute (SACI). SACI is a Comprehensive Cancer Centers designated by the National Cancer Institute.

The objective of the symposium now and for the past 22 years has been to provide a truly international forum for discussion of basic and clinical research in breast cancer. It is designed to provide state-of-the-art information on the experimental, biology, etiology, diagnosis, treatment and prevention of breast cancer to an international audience of academic and private physicians and researchers. Symposium directors are Charles A. Coltman, Jr., MD, President and CEO of CTRC, Profess or of Medicine at UTHSCSA and Director of SACI, and C. Kent Osborne, MD, Director, Breast Center and Professor of Medicine and Cell Biology, Baylor College of Medicine.

Three mini-symposia and a Satellite Symposium are on tap for the week. The mini symposia consist of: Microarray-based Anaylsis of Breast Cancer; ER Structure, Function and Clinical Ability; and Novel Targets for the Treatment of Breast Cancer. The satellite symposium will feature the topic "Targeted Therapies for the Treatment f Breast Cancer." The William L. McGuire Memorial Lecture will be delivered on Wednesday, December 6, by Trevor J. Powles, MD, PhD, Royal Marsden Hpsoital, Sutton, Surrey, England. His topic is, "Molecular markers in breast cancer: Where are we, where are we going."

There are five plenary speakers on the program. Among them is Richard Peto, PhD, University of Oxford. His presentation will provide an overview of the year 2000 results of the EBCTCG. The other speakers and their topics are: Charles L. Loprinzi, MD, from the Mayo Clinic, discussing the study of alternative therapies for patients with breast cancer; C. Thomas Caskey, MD, from Cogene BioTech Venture in Houston, with his presentation "Safe viral vectors provide the opportunity to intitate clinical trials;" Ronald K. Ross, MD, Norris Comprehensive Cancer Center in Los Angeles discussing hormone replacement therapy and breast cancer;" and Laurie L. Fajardo, MD, from the Johns Hopkins Outpatient Center in Baltimore speaking on digital mammography.

Over 440 different presentations will be made over the course of the Symposium, by means of poster sessions and lectures. Also, during the symposium on the evening of December 7, the Susan G. Komen Breast Cancer Foundation will hold their Brinker International Awards Dinner.
-end-


Cancer Therapy & Research Center (CTRC)

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.